pharma · Advanced Solid Tumor · Sarcoma · PRLD
Prelude Therapeutics
Prelude Therapeutics Inc
Prelude Therapeutics is a pharma organization headquartered in Wilmington, USA. It trades on NYSE under ticker PRLD. Primary therapeutic focus areas include Advanced Solid Tumor, Sarcoma, Acute Myeloid Leukemia, Polycyth
Company details
- Status
- Public
- HQ
- 175 Innovation Boulevard, Wilmington, DE 19805, US
- Founded
- 2016
- Employees
- 111
- Programs
- 13
- Drugs
- 5
- Patents
- 16
PRT7732-01
Phase 1 · other · esophageal, gastric, or gastroesophageal junction adenocarcinoma, esophageal, gastric, or gastroesophageal junction squamous cell carcinoma, Non-small cell lung cancer (NSCLC), Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
PRT7732-01 for esophageal, gastric, or gastroesophageal junction adenocarcinoma, esophageal, gastric, or gastroesophageal junction squamous cell carcinoma, Non-small cell lung cancer (NSCLC), Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation is a Phase 1 program (other) at Prelude Therapeutics Inc with 1 ClinicalTrials.gov record(s).
Internal code PRT7732-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Prelude Therapeutics Inc
- Phase
- Phase 1
- Modality
- other
- Indication
- esophageal, gastric, or gastroesophageal junction adenocarcinoma, esophageal, gastric, or gastroesophageal junction squamous cell carcinoma, Non-small cell lung cancer (NSCLC), Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
- Status
- active
- Trials
- 1